Tonix Pharmaceuticals Holding Corp. (TNXP) to Release Quarterly Earnings on Wednesday
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) will announce its earnings results on Wednesday, November 8th. Analysts expect the company to announce earnings of ($0.69) per share for the quarter.
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last announced its earnings results on Monday, August 14th. The company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.78) by $0.13. On average, analysts expect Tonix Pharmaceuticals Holding Corp. to post $-3.0200 EPS for the current fiscal year and $-2.4700 EPS for the next fiscal year.
Shares of Tonix Pharmaceuticals Holding Corp. (TNXP) opened at 3.7015 on Wednesday. The firm’s market capitalization is $27.79 million. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $2.85 and a 52 week high of $9.40. The firm has a 50-day moving average of $4.26 and a 200 day moving average of $4.09.
Several research analysts have commented on TNXP shares. ValuEngine upgraded shares of Tonix Pharmaceuticals Holding Corp. from a “strong sell” rating to a “sell” rating in a report on Friday, September 1st. Drexel Hamilton started coverage on shares of Tonix Pharmaceuticals Holding Corp. in a report on Tuesday, August 22nd. They set a “buy” rating for the company. Dawson James reiterated a “buy” rating and set a $9.00 price target on shares of Tonix Pharmaceuticals Holding Corp. in a report on Wednesday, August 23rd. Finally, Roth Capital upgraded shares of Tonix Pharmaceuticals Holding Corp. from a “neutral” rating to a “buy” rating and set a $6.00 price target for the company in a report on Friday, August 18th. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $8.33.
In other news, CEO Seth Lederman purchased 20,000 shares of the stock in a transaction on Thursday, August 17th. The stock was bought at an average price of $3.00 per share, for a total transaction of $60,000.00. Following the acquisition, the chief executive officer now directly owns 11,166 shares of the company’s stock, valued at approximately $33,498. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.00% of the company’s stock.
An institutional investor recently raised its position in Tonix Pharmaceuticals Holding Corp. stock. Vanguard Group Inc. grew its stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 28.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 184,377 shares of the company’s stock after buying an additional 41,264 shares during the period. Vanguard Group Inc. owned 2.46% of Tonix Pharmaceuticals Holding Corp. worth $799,000 at the end of the most recent reporting period. Institutional investors own 22.98% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Tonix Pharmaceuticals Holding Corp. (TNXP) to Release Quarterly Earnings on Wednesday” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/11/01/tonix-pharmaceuticals-holding-corp-tnxp-to-release-quarterly-earnings-on-wednesday.html.
Tonix Pharmaceuticals Holding Corp. Company Profile
Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The companys lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.
Receive News & Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related companies with MarketBeat.com's FREE daily email newsletter.